



SAKK/AMGEN Research Grant 2017

SAKK and AMGEN are highly interested in innovative and practice relevant oncology research that improves patient's lives. With that aspiration, SAKK conducts important clinical studies and AMGEN develops innovative drugs to manage serious illnesses.

For the seventh time, SAKK and AMGEN award a grant for outstanding and novel translational cancer research.

The call for proposals for the SAKK/AMGEN Research Grant 2017 is open.

The deadline for submission is **August 31, 2017**.

- The grant is endowed with **CHF 50'000.-** and will be given to a researcher or a research team from a Swiss hospital or institution conducting translational cancer research (oncology/hematology).
- The grant should contribute to an independent research project, predominately be performed in Switzerland, and should cover a substantial scientific part of the project. The submitted research project should not be a small translational part of a large clinical trial.
- The criteria to determine the winning project are: novelty, clinical relevance and feasibility.
- The independent jury, chaired by Prof. Roger von Moos (SAKK President), will evaluate the proposals.
- The grant will be awarded at the SAKK semi-annual meeting in November 2017 and will be published in the Swiss Cancer Bulletin.

The proposal must comprise the completed application form, an anonymous project description in English (max. 3 pages, comprising a short summary (novelty, relevance) and a project overview incl. work plan with timelines (feasibility), budget estimation and references) and a CV of the applicant (team lead).

The submissions should be sent electronically to: researchgrant.ch@amgen.com. The regulations for the grant and the application form can be downloaded from http://www.amgen.ch/german/medpro/research_grant.html.

For more information, please contact:
Dr. Christian Merkle, Therapeutic Area Head Oncology,
AMGEN Switzerland AG, E-Mail: researchgrant.ch@amgen.com,
Tel. Direct line: 041 369 01 85